IDH2 and astrocytoma (excluding glioblastoma): In the dose expansion phase (using 1500 mg and twice daily dosing), 25 were considered “low-grade glioma” (grade 2–3), and 13 were considered IDH-mutant “glioblastoma” (now classified as astrocytoma, IDH-mutant, grade 4) [38].